EGFR and nasopharyngeal carcinoma: As the most commonly used anti-EGFR monoclonal antibody, cetuximab has shown good curative effect in the treatment of NPC; however, its use is associated with severe adverse reactions, such as oral mucositis and itchy rash [26].